Rapid Test Kits (HIV, HBV, HCV, Malaria)

Name: Rapid Test Kits (HIV, HBV, HCV, Malaria) - Amaris Medical Solutions
Price: 1.00 USD
Availability: InStock

$1.00

WhatsApp Order

Rapid Test Kits for HIV, HBV, HCV, and Malaria are single-use, immunochromatographic devices designed for the quick, preliminary screening of these critical infectious diseases at the point of care. By detecting specific antibodies or antigens in a small blood sample (or oral fluid for some HIV tests), they provide a visual result within 15-30 minutes without the need for laboratory equipment. Their primary role is to expand access to testing in community and resource-limited settings, enabling immediate counseling, triage, and referral for confirmatory testing and treatment. As essential tools in public health, they are characterized by their simplicity, speed, and critical importance in early diagnosis and outbreak response.

Compare

Add to wishlist

Categories: DIAGNOSTIC EQUIPMENT, CONSUMABLES AND DISPOSABLES, Diagnostic Kits Tags: DiagnosticKit, HepatitisTest, HIVTest, MalariaTest, PointOfCare, RapidTestKit, ScreeningTest

Description

Rapid Test Kits (HIV, HBV, HCV, Malaria)

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Point-of-Care (POC) Screening for Infectious Diseases:

Primary Use: The primary use is to provide rapid, preliminary screening for specific infections at or near the site of patient care. This enables immediate triage, initial diagnosis, and prompt initiation of counseling and referral in settings without access to central laboratory facilities, such as community health clinics, emergency departments, outreach programs, and resource-limited areas.
How it helps: Brings life-saving diagnostic capability to the places where people live and seek care, eliminating the days or weeks of waiting for lab results that can mean the difference between starting treatment and being lost to follow-up.

2. Blood Donor Safety Screening (in some settings):

Primary Use: Used in blood banks and donation camps in low-resource regions to provide an immediate screening layer for transfusion-transmissible infections (HIV, HBV, HCV) to enhance blood safety prior to more sophisticated confirmatory testing.
How it helps: Provides an essential safety net for blood transfusion services in areas where laboratory infrastructure is limited, catching infected donations before they can be given to recipients.

3. Public Health Surveillance and Outbreak Investigation:

Primary Use: Deployed in field settings during disease outbreaks (e.g., malaria epidemics) or for population-level serosurveys to quickly map disease prevalence and guide public health interventions.
How it helps: Empowers public health officials to track diseases in real-time during outbreaks, identifying hotspots and guiding resource allocation to contain epidemics before they spread further.

4. Pre- and Post-Test Counseling Tool:

Primary Use: The rapid turnaround time (10-30 minutes) allows healthcare providers to deliver results during a single visit, facilitating immediate counseling, discussion of risk reduction, and planning for confirmatory testing and linkage to care if reactive.
How it helps: Ensures that no patient is lost to follow-up between testing and result delivery, providing immediate support and connection to care for those who test positive.

5. Prenatal Screening:

Primary Use: Used in antenatal clinics to screen pregnant women for infections like HIV, HBV, and syphilis (often combined) to enable timely interventions that prevent mother-to-child transmission.
How it helps: Protects the most vulnerable—newborn babies—by identifying infections in pregnant women early and providing treatment that can prevent transmission during pregnancy and birth.

SECONDARY & SUPPORTIVE USES

1. Occupational Health Post-Exposure Prophylaxis (PEP) Decisions: Following a needlestick or other occupational exposure to blood, a rapid test on the source patient can provide critical information to guide the urgency and type of PEP for the healthcare worker, offering peace of mind and guiding treatment.

2. Self-Testing (for specific approved kits): Certain HIV self-test kits are designed for use by individuals in private, increasing access to testing for those who might not visit a clinic and empowering people to take control of their health.

3. Diagnostic Support in Remote Areas: Serves as the primary diagnostic tool for malaria in remote regions where microscopy is unavailable, guiding immediate antimalarial treatment and preventing deaths from this preventable disease.

KEY PRODUCT FEATURES

1. BASIC IDENTIFICATION ATTRIBUTES

Device Type: In Vitro Diagnostic (IVD) Rapid Diagnostic Test (RDT).
Format: Typically lateral flow immunochromatographic assays (similar to a pregnancy test). Some may be in cassette, dipstick, or card formats.
Sample Types: Varies by kit. Common samples include whole blood (from fingerstick or venipuncture), serum, plasma, or oral fluid (for some HIV tests).
Target Pathogens/Analytes:
- HIV: Detects antibodies (Ab) to HIV-1/2 and/or p24 antigen (Ag) (4th generation combo tests).
- HBV: Detects Hepatitis B surface Antigen (HBsAg).
- HCV: Detects antibodies to Hepatitis C virus.
- Malaria: Detects specific parasite antigens (e.g., HRP-2 for P. falciparum, pLDH for other species).

2. TECHNICAL & PERFORMANCE PROPERTIES

Principle: Based on antigen-antibody reactions. The sample migrates along a nitrocellulose strip. If the target analyte (antibody or antigen) is present, it binds to conjugated colored particles and then to immobilized capture reagents, forming a visible colored line in the test region.
Interpretation:
- Positive/Reactive: A colored line appears in both the Control (C) region and the Test (T) region.
- Negative/Non-Reactive: A colored line appears only in the Control (C) region.
- Invalid: No line in the Control region. The test must be repeated with a new kit.
Time to Result: Typically 15 to 30 minutes.
Sensitivity and Specificity: Must meet minimum WHO performance standards. For example:
- HIV RDTs: Sensitivity >99%, Specificity >98%.
- Malaria RDTs: Detection thresholds around 100-200 parasites/µL.
Shelf Life and Storage: Typically requires storage at 2-30°C. Must be protected from moisture, direct sunlight, and freezing.

3. PHYSICAL & OPERATIONAL PROPERTIES

Packaging: Individually sealed foil pouches containing the test device, a disposable dropper/transfer pipette, buffer solution, and sometimes a lancet and alcohol swab.
Simplicity: Designed for use by trained personnel with minimal laboratory infrastructure. Procedures involve simple steps: sample collection, application, adding buffer, and timed reading.
No Instrumentation Required: Visual readout, no electricity needed.

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Approvals: Must have relevant market authorizations: WHO Prequalification (PQ) is a key benchmark for quality in global health. FDA 510(k) Clearance (US), CE Marking (EU), and approvals from national regulatory bodies (e.g., CDSCO in India) are essential.
Quality Standards: Manufactured under ISO 13485. Performance evaluated against reference standards.
Intended Use: Clearly labeled as a screening test. Reactive (positive) results must be confirmed with supplemental/confirmatory tests (e.g., Western Blot for HIV, Nucleic Acid Test for HCV, microscopy for malaria) as per national algorithms.

5. STORAGE & HANDLING ATTRIBUTES

Storage: Store in a cool, dry place within the specified temperature range. Monitor expiry dates and implement a first-expiry-first-out (FEFO) inventory system.
Transport: Use cold chain (2-8°C) if required for long-term stability, but many kits are stable at ambient temperatures for a defined period.
Waste Disposal: All used components (test devices, lancets, swabs) are considered biohazardous waste and must be disposed of in appropriate sharps and biohazard containers.

6. LABORATORY & CLINICAL APPLICATIONS

Primary Application: A public health and clinical screening tool designed for simplicity and speed, bridging the gap between initial suspicion and confirmatory laboratory diagnosis.
Algorithmic Testing: Often used in serial or parallel testing algorithms (e.g., using two or three different HIV RDTs in sequence) to improve overall accuracy before referral for confirmation.

SAFETY HANDLING PRECAUTIONS

1. SAFETY PRECAUTIONS

Universal Precautions: Handle all blood and body fluid samples as potentially infectious. Wear gloves and other appropriate PPE during testing and waste handling.
Single-Use Only: Every component is for single use only. Do not reuse lancets, pipettes, or test devices.
Strict Adherence to Procedure: Follow the manufacturer's instructions exactly regarding sample volume, incubation time, and interpretation. Reading results too early or too late can lead to errors.
Post-Test Counseling: Have a trained counselor available to deliver results, especially reactive ones, and to provide immediate support, risk reduction information, and a clear plan for confirmatory testing and care linkage.

2. FIRST AID MEASURES

Needlestick or Exposure: In case of a lancet injury or exposure to sample, wash the area immediately with soap and water. For mucosal exposure, rinse thoroughly with water. Follow the facility's post-exposure prophylaxis (PEP) protocol and seek medical evaluation.
Reagent Contact: If buffer solution contacts skin or eyes, rinse with plenty of water.

3. FIRE FIGHTING MEASURES

Flammability: The plastic and paper components are combustible.
Extinguishing Media: Use water, foam, or CO₂ as appropriate for the surrounding fire.

Rapid Test Kits (HIV, HBV, HCV, Malaria)

Rapid Test Kits (HIV, HBV, HCV, Malaria)

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Point-of-Care (POC) Screening for Infectious Diseases:

How it helps: Brings life-saving diagnostic capability to the places where people live and seek care, eliminating the days or weeks of waiting for lab results that can mean the difference between starting treatment and being lost to follow-up.

2. Blood Donor Safety Screening (in some settings):

Primary Use: Used in blood banks and donation camps in low-resource regions to provide an immediate screening layer for transfusion-transmissible infections (HIV, HBV, HCV) to enhance blood safety prior to more sophisticated confirmatory testing.

How it helps: Provides an essential safety net for blood transfusion services in areas where laboratory infrastructure is limited, catching infected donations before they can be given to recipients.

3. Public Health Surveillance and Outbreak Investigation:

Primary Use: Deployed in field settings during disease outbreaks (e.g., malaria epidemics) or for population-level serosurveys to quickly map disease prevalence and guide public health interventions.

How it helps: Empowers public health officials to track diseases in real-time during outbreaks, identifying hotspots and guiding resource allocation to contain epidemics before they spread further.

4. Pre- and Post-Test Counseling Tool:

Primary Use: The rapid turnaround time (10-30 minutes) allows healthcare providers to deliver results during a single visit, facilitating immediate counseling, discussion of risk reduction, and planning for confirmatory testing and linkage to care if reactive.

How it helps: Ensures that no patient is lost to follow-up between testing and result delivery, providing immediate support and connection to care for those who test positive.

5. Prenatal Screening:

Primary Use: Used in antenatal clinics to screen pregnant women for infections like HIV, HBV, and syphilis (often combined) to enable timely interventions that prevent mother-to-child transmission.

How it helps: Protects the most vulnerable—newborn babies—by identifying infections in pregnant women early and providing treatment that can prevent transmission during pregnancy and birth.

SECONDARY & SUPPORTIVE USES

2. Self-Testing (for specific approved kits): Certain HIV self-test kits are designed for use by individuals in private, increasing access to testing for those who might not visit a clinic and empowering people to take control of their health.

3. Diagnostic Support in Remote Areas: Serves as the primary diagnostic tool for malaria in remote regions where microscopy is unavailable, guiding immediate antimalarial treatment and preventing deaths from this preventable disease.

1. BASIC IDENTIFICATION ATTRIBUTES

Device Type: In Vitro Diagnostic (IVD) Rapid Diagnostic Test (RDT).

Format: Typically lateral flow immunochromatographic assays (similar to a pregnancy test). Some may be in cassette, dipstick, or card formats.

Sample Types: Varies by kit. Common samples include whole blood (from fingerstick or venipuncture), serum, plasma, or oral fluid (for some HIV tests).

Target Pathogens/Analytes:

HIV: Detects antibodies (Ab) to HIV-1/2 and/or p24 antigen (Ag) (4th generation combo tests).

HBV: Detects Hepatitis B surface Antigen (HBsAg).

HCV: Detects antibodies to Hepatitis C virus.

Malaria: Detects specific parasite antigens (e.g., HRP-2 for P. falciparum, pLDH for other species).

2. TECHNICAL & PERFORMANCE PROPERTIES

Principle: Based on antigen-antibody reactions. The sample migrates along a nitrocellulose strip. If the target analyte (antibody or antigen) is present, it binds to conjugated colored particles and then to immobilized capture reagents, forming a visible colored line in the test region.

Interpretation:

Positive/Reactive: A colored line appears in both the Control (C) region and the Test (T) region.

Negative/Non-Reactive: A colored line appears only in the Control (C) region.

Invalid: No line in the Control region. The test must be repeated with a new kit.

Time to Result: Typically 15 to 30 minutes.

Sensitivity and Specificity: Must meet minimum WHO performance standards. For example:

HIV RDTs: Sensitivity >99%, Specificity >98%.

Malaria RDTs: Detection thresholds around 100-200 parasites/µL.

Shelf Life and Storage: Typically requires storage at 2-30°C. Must be protected from moisture, direct sunlight, and freezing.

3. PHYSICAL & OPERATIONAL PROPERTIES

Packaging: Individually sealed foil pouches containing the test device, a disposable dropper/transfer pipette, buffer solution, and sometimes a lancet and alcohol swab.

Simplicity: Designed for use by trained personnel with minimal laboratory infrastructure. Procedures involve simple steps: sample collection, application, adding buffer, and timed reading.

No Instrumentation Required: Visual readout, no electricity needed.

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Approvals: Must have relevant market authorizations: WHO Prequalification (PQ) is a key benchmark for quality in global health. FDA 510(k) Clearance (US), CE Marking (EU), and approvals from national regulatory bodies (e.g., CDSCO in India) are essential.

Quality Standards: Manufactured under ISO 13485. Performance evaluated against reference standards.

Intended Use: Clearly labeled as a screening test. Reactive (positive) results must be confirmed with supplemental/confirmatory tests (e.g., Western Blot for HIV, Nucleic Acid Test for HCV, microscopy for malaria) as per national algorithms.

5. STORAGE & HANDLING ATTRIBUTES

Storage: Store in a cool, dry place within the specified temperature range. Monitor expiry dates and implement a first-expiry-first-out (FEFO) inventory system.

Transport: Use cold chain (2-8°C) if required for long-term stability, but many kits are stable at ambient temperatures for a defined period.

Waste Disposal: All used components (test devices, lancets, swabs) are considered biohazardous waste and must be disposed of in appropriate sharps and biohazard containers.

6. LABORATORY & CLINICAL APPLICATIONS

Primary Application: A public health and clinical screening tool designed for simplicity and speed, bridging the gap between initial suspicion and confirmatory laboratory diagnosis.

Algorithmic Testing: Often used in serial or parallel testing algorithms (e.g., using two or three different HIV RDTs in sequence) to improve overall accuracy before referral for confirmation.

1. SAFETY PRECAUTIONS

Universal Precautions: Handle all blood and body fluid samples as potentially infectious. Wear gloves and other appropriate PPE during testing and waste handling.

Single-Use Only: Every component is for single use only. Do not reuse lancets, pipettes, or test devices.

Strict Adherence to Procedure: Follow the manufacturer's instructions exactly regarding sample volume, incubation time, and interpretation. Reading results too early or too late can lead to errors.

Post-Test Counseling: Have a trained counselor available to deliver results, especially reactive ones, and to provide immediate support, risk reduction information, and a clear plan for confirmatory testing and care linkage.

2. FIRST AID MEASURES

Needlestick or Exposure: In case of a lancet injury or exposure to sample, wash the area immediately with soap and water. For mucosal exposure, rinse thoroughly with water. Follow the facility's post-exposure prophylaxis (PEP) protocol and seek medical evaluation.

Reagent Contact: If buffer solution contacts skin or eyes, rinse with plenty of water.

3. FIRE FIGHTING MEASURES

Flammability: The plastic and paper components are combustible.

Extinguishing Media: Use water, foam, or CO₂ as appropriate for the surrounding fire.

Related products

BRANDS

FOLLOW US